Clinical Trial Update: Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and immunogenicity of a recombinant HPV bivalent vaccine targeting types 16/18; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Intraepithelial Neoplasia
• Persistent Infection
• Vaginal Intraepithelial Neoplasia
• Vulvar Intraepithelial Neoplasia

Drugs mentioned

• Recombinant Human Papillomavirus Bivalent (Type 16/18) Vaccine (HPV16/18 bivalent vaccine)

Snippet

Sponsor: Xiamen University | Conditions: Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 3 | Status: COMPLETED